Recovering from COVID-19 ReCOV: Feasibility of an Allied-Health-Led Multidisciplinary Outpatient Rehabilitation Service, 2024, D’Souza+

SNT Gatchaman

Senior Member (Voting Rights)
Staff member
Recovering from COVID-19 ReCOV: Feasibility of an Allied-Health-Led Multidisciplinary Outpatient Rehabilitation Service for People with Long COVID
D’Souza, Aruska N.; Merrett, Myvanwy; Griffin, Hilda; Tran-Duy, An; Struck, Carly; Fazio, Timothy N.; Juj, Genevieve; Granger, Catherine L.; Peiris, Casey L.

BACKGROUND
A multidisciplinary approach is required for the management of long COVID. The aim of this study was to determine the feasibility (demand, implementation, practicality, acceptability, and limited efficacy) of an allied-health-led multidisciplinary symptom management service (ReCOV) for long COVID.

METHODS
A single-group observational cohort feasibility study was conducted to determine demand (referrals), acceptability (survey), implementation (waitlist times, health professions seen), practicality (adverse events), and limited efficacy (admission and discharge scores from the World Health Organization Disability Assessment Scale, Brief Illness Perception Questionnaire (BIPQ), Patient Health Questionnaire, and EuroQol 5D-5L). Data are presented as median [interquartile range] or count (percentage).

RESULTS
During the study, 143 participants (aged 42.00 [32.00–51.00] years, 68% women) participated in ReCOV. Participants were waitlisted for 3.86 [2.14–9.86] weeks and engaged with 5.00 [3.00–6.00] different health professionals. No adverse events occurred. The thematic analysis revealed that ReCOV was helpful but did not fully meet the needs of all participants. Limited efficacy testing indicated that participants had improved understanding and control (p < 0.001) of symptoms (BIPQ) and a small improvement in EQ VAS score (median difference 5.50 points [0.00–25.00], p = 0.004]).

CONCLUSIONS
A multidisciplinary service was safe and mostly acceptable to participants for the management of long COVID. Further research should investigate the clinical and cost effectiveness of such a service, including optimal service duration and patient outcomes.

Link | PDF (International Journal of Environmental Research and Public Health) [Open Access]
 
Thirty-nine (27%) completed the discharge limited efficacy testing survey. Following ReCOV, participants reported some improvement in EQ VAS scores (median difference 5.5 [IQR 0–25.5]) and symptoms, but no change in overall disability on the WHODAS 2.0 (median difference 0 [0–0]) was observed. Moreover, mean health utility values at discharge were higher than those at admission, although the difference in health utility values was not significant. Similarly, participants observed no change in their symptoms but reported improvements in their overall understanding and control of their illness as per the BIPQ.
 
Back
Top Bottom